Researchers at Mayo Clinic say they have identified five biologically distinct subtypes of a common liver disease that affects nearly 30% of adults worldwide, a finding that could help doctors detect high-risk patients earlier and move toward more personalized care. The study, published in Nature Communications, suggests that metabolic dysfunction-associated steatotic liver disease is not a single condition but a group of disorders with different biological pathways and different risks for serious outcomes.
Why the findings matter for earlier intervention
According to the Mayo Clinic report, the different subtypes carry varying risks for heart disease, liver failure, cancer and the need for liver transplantation. The researchers said some forms appear to be tied more closely to obesity and diabetes, while others are driven by inherited genetic factors. That distinction could be important in identifying patients who may progress to advanced liver disease even when they do not have the usual metabolic risk factors.
“When clinical and genomic data are analyzed together at this scale, you begin to see patterns of disease progression that would otherwise remain hidden,” co-senior author Shulan Tian said in the report. The team said the results could help match treatments to the biology driving the disease rather than relying on a one-size-fits-all approach.
Large-scale data revealed hidden biological patterns
The research combined genetic sequencing with detailed clinical data from more than 4,600 patients. The dataset included measures such as liver enzymes, body mass index and lipid levels, along with information on coexisting conditions including diabetes, depression and sleep apnea. Using computational modeling, the researchers identified patient groups that shared underlying biological signals and defined the five subtypes.
Eric Klee, another co-senior author, said the work shows how complex disease can be mapped with enough precision to anticipate its course and intervene before the most serious damage occurs. The study was supported by Mayo Clinic’s Research Data Atlas and its Tapestry Study, which has generated Mayo Clinic’s largest collection of exome data from more than 100,000 participants.
Broader effects beyond the liver
The study also found links between specific liver-disease subtypes and conditions such as depression, sleep apnea and migraine, underscoring the condition’s wider impact across multiple organ systems. The researchers said they next plan to test the approach in broader patient populations and explore how the subtypes respond to different treatments, including GLP-1 receptor agonists.
The findings add to growing evidence that common diseases may hide important biological subgroups that are missed when patients are treated as one broad category. If confirmed in future studies, the approach could influence screening strategies and open the door to more targeted treatment decisions for people with fatty liver disease.
Photo source: AI-generated or edited image
